#biotechindustry — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #biotechindustry, aggregated by home.social.
-
Unlock top career opportunities in Bioinformatics with BioResire!
Leading companies in Bangalore and Hyderabad are hiring skilled professionals.
Advance your future with the best industry connections and real-world guidance.
Join BioResire to start your journey toward a successful bioinformatics career!#BioinformaticsJobs #DataScience #Genomics #LifeScienceCareers #BioinformaticsTraining #BiotechIndustry #NextGenCareers #STEMEducation #HealthcareIT #ClinicalResearch #DigitalHealth #JobSearch
-
Samsung Biologics announces spin-off to separate CDMO and biosimilar businesses, aiming to resolve conflicts of interest and secure growth momentum in both sectors.
#YonhapInfomax #SamsungBiologics #CDMO #Biosimilars #CorporateRestructuring #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64326 -
Samsung Biologics announces spin-off to create Samsung Epis Holdings, sparking market speculation about potential governance restructuring and impacting stock prices of Samsung C&T and Samsung Biologics.
#YonhapInfomax #SamsungBiologics #SpinOff #SamsungCT #GovernanceRestructuring #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64316 -
Samsung Biologics maintains its financial outlook for the year, indicating stability in its business operations despite recent corporate restructuring
#YonhapInfomax #SamsungBiologics #FinancialGuidance #CorporateSplit #BiotechIndustry #BusinessOutlook #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64304 -
Samsung Biologics clarifies it is not currently considering an initial public offering for its subsidiary Samsung Bioepis, dispelling market speculation
#YonhapInfomax #SamsungBiologics #SamsungBioepis #IPO #BiotechIndustry #CorporateStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64302 -
Samsung Biologics announces corporate restructuring, splitting into two entities to enhance operational efficiency and focus on core business areas
#YonhapInfomax #SamsungBiologics #CorporateRestructuring #CompanySplit #SamsungEpisHoldings #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64251 -
Samsung Biologics announces strategic split, forming separate entities Samsung Biologics and Samsung Epis Holdings to enhance operational focus and market competitiveness
#YonhapInfomax #SamsungBiologics #CorporateSplit #SamsungEpisHoldings #BiotechIndustry #CorporateRestructuring #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64250 -
SK Bioscience reports Q1 operating loss of 15.1 billion won, outperforming market expectations amid challenging biotech landscape
#YonhapInfomax #SKBioscience #Q1Results #OperatingLoss #BiotechIndustry #FinancialPerformance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61986 -
ABL Bio secures major $3.4 billion technology transfer deal with GSK for 'Grabody-B' drug development platform, marking second-largest biotech agreement in South Korea
#YonhapInfomax #ABLBio #GlaxoSmithKline #TechnologyTransfer #GrabodyB #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=57545 -
US biotech firm Terns Pharmaceuticals sees potential 5-fold stock increase on promising obesity drug developments and analyst optimism
#YonhapInfomax #TernsPharmaceuticals #ObesityDrug #GLP1 #StockForecast #BiotechIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=53550 -
Samsung Biologics and Celltrion report record sales for 2023, while industry watches potential impact of Trump's pharmaceutical tariff considerations
#YonhapInfomax #SamsungBiologics #Celltrion #RecordSales #BiotechIndustry #TrumpTariffs #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=51151